Navigation Links
Shire Receives LIALDA(R) Paragraph IV Notice Letter From Zydus Pharmaceuticals
Date:5/28/2010

DUBLIN, May 28, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has received a Paragraph IV Notice Letter today from Zydus Pharmaceuticals USA, Inc. ("Zydus") advising of the filing of an Abbreviated New Drug Application ("ANDA") for a generic version of Shire's 1.2g mesalamine delayed release tablets, LIALDA(R).

LIALDA is protected by the following FDA Orange Book listed patent: U.S. Patent No. 6,773,720, Mesalazine Controlled Release Pharmaceutical Compositions (the "'720 patent"). The patent expires in 2020.

Shire is currently reviewing the details of Zydus' Paragraph IV Notice Letter. Under the Hatch-Waxman Act, Shire has 45 days from the receipt of the Notice Letter to determine if it will file a patent infringement suit. If Shire brings suit pursuant to the Hatch Waxman regulations, a stay of approval of up to 30-months will be imposed by the FDA on Zydus' ANDA.

Notes to Editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of produ
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Mar. 05, 2015 Research and Markets ... "Japan Pharma Outlook 2015: Year to Watch out ... report to their offering. The ... from April -2014 (Annexure 1) is a game ... whether generic or innovator. The most of the companies ...
(Date:3/5/2015)... 2015 Hitachi Medical Systems ... OASIS *    at ECR 2015 - the ... set a benchmark for patient-centric care. The new features ... whilst optimizing workflow management and costs. OASIS demonstrates the ... for imaging in Neurology, Orthopaedics, Paediatrics, Oncology, Vascular and ...
(Date:3/5/2015)... VIENNA , March 5, 2015 ... Aloka Medical Ltd., Tokyo, Japan , ... extraordinary compact, portable Ultrasound Bone Densitometry System at the ... to see and test EggQus at the Hitachi Medical ... http://photos.prnewswire.com/prnh/20150305/732754-a ) ,      (Photo: ...
Breaking Medicine Technology:Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 2Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 3Hitachi Medical Systems Europe Launches the New Generation of OASIS*- The World's Most Powerful Open High-Field 1.2T MRI - A New Level in Patient-Centric Care 2Hitachi Medical Systems Europe Launches the New Generation of OASIS*- The World's Most Powerful Open High-Field 1.2T MRI - A New Level in Patient-Centric Care 3Hitachi Aloka Medical, Ltd. Introduces EggQus AOS 100E - a Compact and Lightweight Ultrasound Bone Densitometry System 2Hitachi Aloka Medical, Ltd. Introduces EggQus AOS 100E - a Compact and Lightweight Ultrasound Bone Densitometry System 3
... Generex Biotechnology Corporation ( www.generex.com ) (OTC Bulletin ... peer-reviewed scientific journal Diabetes, Obesity and Metabolism ... Oral-lyn™, the Company,s proprietary buccal insulin spray product. ... subjects with impaired glucose tolerance: the prevoral study , ...
... Bionovo, Inc. (Nasdaq: BNVI ), a pharmaceutical company ... women,s health and cancer, today announced that it had received ... Clinical Guidance meeting that took place on November 8, 2010. ... overall clinical development plan. "We had a ...
Cached Medicine Technology:Generex Announces Publication of New Positive Generex Oral-lyn™ Data in Peer-Reviewed Journal 2Generex Announces Publication of New Positive Generex Oral-lyn™ Data in Peer-Reviewed Journal 3Generex Announces Publication of New Positive Generex Oral-lyn™ Data in Peer-Reviewed Journal 4Generex Announces Publication of New Positive Generex Oral-lyn™ Data in Peer-Reviewed Journal 5Bionovo Releases FDA-Approved Clinical Development Plan for Menerba 2Bionovo Releases FDA-Approved Clinical Development Plan for Menerba 3Bionovo Releases FDA-Approved Clinical Development Plan for Menerba 4
(Date:3/5/2015)... A Bakersfield, Calif. state court jury returned a verdict this ... Coleen M. Perry a total of $5.7 million for damages ... sling device, manufactured by Ethicon, Inc., a subsidiary of Johnson ... Wagstaff & Cartmell in Kansas City, Mo., was ... Freese and Tim Goss of Freese & Goss ...
(Date:3/5/2015)... York (PRWEB) March 05, 2015 Testosterone ... who allegedly suffered heart attacks, strokes and other serious ... testosterone therapies continue to move forward in the federal ... District of Illinois. According to a Case Management Order ... procedures for the use of master pleadings in the ...
(Date:3/5/2015)... 2015 HomeCEUConnection.com is proud ... extra savings on their nutrition CEUs. To ... and nutrition, HomeCEUConnection.com is offering 10% off ... code, NUTRITION2015 . , High Quality ... HomeCEUConnection.com provides high-quality continuing education courses for ...
(Date:3/5/2015)... 05, 2015 SuperCloset has released a new ... series aims to teach viewers everything they need to know ... Like a SuperPro takes you from seed all the way ... clone, to how to prune Grow Like a SuperPro will ... the whole series for download for a special introductory price ...
(Date:3/5/2015)... At the 7th Annual Mississippi Addiction ... treatment met today in Jackson, Mississippi to listen to ... the numerous respected speakers will be William S. ... that pain medications have had in today’s opiate overdose ... "It is hard to believe that much of the ...
Breaking Medicine News(10 mins):Health News:Client Wins $5.7 Million in TVT-Abbrevo Verdict against Johnson & Johnson in California State Court 2Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 2Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 3Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 4Health News:HomeCEUConnection.com Offers Nutrition CEUs this March to Celebrate Nutrition Month 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 3
... zero in (on) the modalities of a drug, capable of ... trials on animal models have revealed the capacity of the ... charge of energy production., ,'Many drugs block the ... who is the Werner E. Bachmann Collegiate Professor of Chemistry ...
... renowned medical specialist, NHS can be freed from its’ ... reconsidered before they are implemented. // It is amply ... may make matters worse for the deprived and under ... has led to low morale among Doctors and NHS ...
... has announced the launch of BARACLUDE? (entecavir) for ... its approval by the Drug Controller General of India. ... of chronic hepatitis B virus infection in adults with ... persistent elevations in serum aminotransferases (ALT or AST) or ...
... warned that hospitals are repeatedly failing to implement rules ... to patients //from contaminated surgical instruments. ,The ... in sets so they can be traced easily. Instead ... ,Dr Gill Morgan, chief executive of the NHS ...
... with medical services functioning smoothly and the institute's director ... and attending to patients - a day after the ... ,While health services normalised in AIIMS after doctors, ... their agitation last evening following the court order, the ...
... diseases that has affected everyone from Henry VIII to Christoper ... near the site of infection//. The primary sore first appears ... clear. , This is followed by generalized skin rash, ... few months or years later tertiary syphilis develops which destroys ...
Cached Medicine News:Health News:Autoimmune disorders studied in detail by U-M researchers. 2Health News:India Approves Baraclude? (entecavir) For ,Treatment Of Chronic HEPATITIS B 2
... The Bledsoe Revolution Knee ... speed fitting under post-op ... the surgeon or authorized ... post-op fitting and application ...
The Bledsoe Post-Op Knee Brace is designed to provide maximum protection without sacrificing comfort and quick, easy application....
... Room Knee Brace frees the ... the time-consuming post-op fitting and ... more complex brace designs. The ... provides the same benefits as ...
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
Medicine Products: